Persistent disease-associated mutations detected in the bone marrow 30 days after stem cell transplantation are associated with an increased risk for disease progression among patients with myelodysplastic syndrome, research shows.
The ESMO Translational Research and Precision Medicine Working Group has proposed a classification system that orders the value of molecular aberrations as oncologic clinical targets based on the supporting evidence available.
Most patients being treated in the community setting for advanced nonsquamous non-small-cell lung cancer do not benefit from the use of broad-based genomic sequencing, suggests a study comparing this approach with routine testing for only epidermal growth factor receptor and anaplastic lymphoma kinase alterations.
Carriers of the C−509T allele in the transforming growth factor ß 1 gene have a significantly increased risk for late breast fibrosis following breast-conserving surgery and whole-breast irradiation for stage 0 to IIA breast cancer, researchers report.
In patients with epidermal growth factor receptor-mutated non-small-cell lung cancer, the presence of concomitant mutations in other cancer-related genes is associated with worse outcomes in response to EGFR tyrosine kinase inhibitors, Chinese research suggests.
The presence of molecular minimal residual disease, identified by next-generation targeted sequencing, is associated with a significantly increased risk for relapse or death in patients with acute myeloid leukemia, study findings indicate.
A polygenic hazard score that evaluates an individual’s age-related risk for developing prostate cancer could help guide personalized decision making about prostate-specific antigen screening, say researchers.
Researchers have warned that underuse of mismatch repair deficiency testing “is a persistent and pervasive problem” in the USA, even among young adults with colorectal cancer where its use is unequivocally recommended.
Mutations in the TP53 gene are the strongest independent predictor of reduced survival after allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome, results of a genetic profiling study show.